Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction

Toxicology and Applied Pharmacology

Volumn 271, Issue 1, 2013, Pages 95-105

  Jin, So Hee ^a   Yang, Ji Hye ^a   Shin, Bo Yeon ^a   Seo, Kyuhwa ^a   Shin, Sang Mi ^a   Cho, Il Je ^b   Ki, Sung Hwan ^a  

^a Chosun University   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

Hepatic lipogenesis; Liver X receptor ; Resveratrol; Sestrin; Sterol regulatory element binding protein 1c

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER X RECEPTOR ALPHA; LUCIFERASE; PROTEIN; RESVERATROL; RETINOID X RECEPTOR ALPHA; SESTRIN 2 PROTEIN; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; FATTY LIVER; GENE INDUCTION; GENE SILENCING; GENE TARGETING; LIPID DIET; LIPID LIVER LEVEL; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSACTIVATION;

ACC; ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASE; AMPK; DN-AMPK; DOMINANT-NEGATIVE AMP-ACTIVATED PROTEIN KINASE; FARNESOID X RECEPTOR; FAS; FATTY ACID SYNTHASE; FXR; GLUTATHIONE; GSH; HEPATIC LIPOGENESIS; HFD; HIGH-FAT DIET; LIVER X RECEPTOR ELEMENTS; LIVER X RECEPTOR- Α; LIVER X RECEPTOR-Α; LXRΑ; LXRE; NAFLD; NASH; NF-E2-RELATED FACTOR 2; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; NRF2; PREGNANE X RECEPTOR; PXR; REACTIVE OXYGEN SPECIES; RESVERATROL; RETINOID X RECEPTOR; ROS; RXR; SCD-1; SESN; SESTRIN; SIRT1; SIRTUIN 1; SREBP-1C; STEAROYL-COA DESATURASE-1; STEROL REGULATORY ELEMENT BINDING PROTEIN-1C; T090; T0901317;

ANIMALS; ANTIOXIDANTS; CELL CYCLE PROTEINS; DIET, HIGH-FAT; GENE KNOCKDOWN TECHNIQUES; HEAT-SHOCK PROTEINS; HEP G2 CELLS; HUMANS; HYDROCARBONS, FLUORINATED; LIPOGENESIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; ORPHAN NUCLEAR RECEPTORS; PROTEINS; RNA, SMALL INTERFERING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STILBENES; SULFONAMIDES; UP-REGULATION;

MUS;

EID: 84879317476     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.023     Document Type: Article

References (44)

1. Ai Z.L., Chen D.F. The significance and effects of liver X receptor alpha in nonalcoholic fatty liver disease in rats. Zhonghua Gan Zang Bing Za Zhi 2007, 15:127-130.
2. Bae S.H., Sung S.H., Oh S.Y., Lim J.M., Lee S.K., Park Y.N., Lee H.E., Kang D., Rhee S.G. Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab. 2013, 17:73-84.
3. Baur J.A., Baur D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
4. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114:147-152.
5. Budanov A.V., Shoshani T., Faerman A., Zelin E., Kamer I., Kalinski H., Gorodin S., Fishman A., Chajut A., Einat P., Skaliter R., Gudkov A.V., Chumakov P.M., Feinstein E. Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene 2002, 21:6017-6031.
6. Budanov A.V., Sablina A.A., Feinstein E., Koonin E.V., Chumakov P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004, 304:596-600.
7. Castrillo A., Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 2004, 20:455-480.
8. Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11245-11250.
9. Choe S.S., Choi A.H., Lee J.W., Kim K.H., Chung J.J., Park J., Lee K.M., Park K.G., Lee I.K., Kim J.B. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes 2007, 56:1534-1543.
10. Danz E.D., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic. Biol. Med. 2009, 46:1589-1597.
11. Grefhorst A., Elzinga B.M., Voshol P.J., Plösch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277:34182-34190.
12. Han C.Y., Ki S.H., Kim Y.W., Noh K., Lee, da Y., Kang B., Ryu J.H., Jeon R., Kim E.H., Hwang S.J., Kim S.G. Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation. Antioxid. Redox Signal. 2011, 14:187-202.
13. Higuchi N., Kato M., Shundo Y., Tajiri H., Tanaka M., Yamashita N., Kohjima M., Kotoh K., Nakamuta M., Takayanagi R., Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 2008, 38:1122-1129.
14. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
15. Hwahng S.H., Ki S.H., Bae E.J., Kim H.E., Kim S.G. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009, 49:1913-1925.
16. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 2002, 277:11019-11025.
17. Kay H.Y., Won Yang J., Kim T.H., Lee, da Y., Kang B., Ryu J.H., Jeon R., Kim S.G. Ajoene, a stable garlic by-product, has an antioxidant effect through Nrf2-mediated glutamate-cysteine ligase induction in HepG2 cells and primary hepatocytes. J. Nutr. 2010, 140:1211-1219.
18. Kay H.Y., Kim W.D., Hwang S.J., Choi H.S., Gilroy R.K., Wan Y.J., Kim S.G. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid. Redox Signal. 2011, 15:2135-2146.
19. Kitada M., Kume S., Imaizumi N., Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011, 60:634-643.
20. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
21. Lan F., Cacicedo J.M., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283:27628-27635.
22. Lee J.H., Budanov A.V., Talukdar S., Park E.J., Park H.L., Park H.W., Bandyopadhyay G., Li N., Aghajan M., Jang I., Wolfe A.M., Perkins G.A., Ellisman M.H., Bier E., Scadeng M., Foretz M., Viollet B., Olefsky J., Karin M. Maintenance of metabolic homeostasis by sestrin2 and sestrin3. Cell Metab. 2012, 16:311-321.
23. Leonard S.S., Xia C., Jiang B.H., Stinefelt B., Klandorf H., Harris G.K., Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309:1017-1026.
24. Mader I., Wabitsch M., Debatin K.M., Fischer-Posovszky P., Fulda S. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. FASEB J. 2010, 24:1997-2009.
25. Mitro N., Vargas L., Romeo R., Koder A., Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 2007, 581:1721-1726.
26. Okada K., Warabi E., Sugimoto H., Horie M., Gotoh N., Tokushige K., Hashimoto E., Utsunomiya H., Takahashi H., Ishii T., Yamamoto M., Shoda J. Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J. Gastroenterol. 2013, 48:620-632.
27. Oliveira C.P., da Costa Gayotto L.C., Tatai C., Della Bina B.I., Janiszewski M., Lima E.S., Abdalla D.S., Lopasso F.P., Laurindo F.R., Laudanna A.A. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J. Cell Mol. Med. 2002, 6:399-406.
28. Pandey K.B., Rizvi S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell Longev. 2009, 2:270-278.
29. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 2002, 8:1243-1248.
30. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
31. Rubiolo J.A., Mithieux G., Vega F.V. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 2008, 591:66-72.
32. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
33. Shin S.M., Cho I.J., Kim S.G. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol. Pharmacol. 2009, 76:884-895.
34. Shin B.Y., Jin S.H., Cho I.J., Ki S.H. Nrf2-ARE pathway regulates induction of Sestrin-2 expression. Free Radic. Biol. Med. 2012, 53:834-841.
35. Steffensen K.R., Gustafsson J.A. Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004, 53:S36-S42.
36. Stoeckman A.K., Towle H.C. The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. J. Biol. Chem. 2002, 277:27029-27035.
37. Tennen R.I., Michishita-Kioi E., Chua K.F. Finding a target for resveratrol. Cell 2012, 148:387-389.
38. Vacca M., Degirolamo C., Mariani-Costantini R., Palasciano G., Moschetta A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011, 3:562-587.
39. Videla L.A., Rodrigo R., Orellana M., Fernandez V., Tapia G., Quiñones L., Varela N., Contreras J., Lazarte R., Csendes A., Rojas J., Maluenda F., Burdiles P., Diaz J.C., Smok G., Thielemann L., Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond.) 2004, 106:261-268.
40. Woo H.A., Bae S.H., Park S., Rhee S.G. Sestrin 2 is not a reductase for cysteine sulfinic acid of peroxiredoxins. Antioxid. Redox Signal. 2009, 11:739-745.
41. Yang S., Zhu H., Li Y., Lin H., Gabrielson K., Trush M.A., Diehl A.M. Mitochondrial adaptations to obesity-related oxidant stress. Arch. Biochem. Biophys. 2000, 378:259-268.
42. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
43. Zhao C., Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J. Endocrinol. 2010, 204:233-240.
44. Zhu H., Jia Z., Misra H., Li Y.R. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J. Dig. Dis. 2012, 13:133-142.